{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:24:13Z","timestamp":1790972653714,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.urology.2025.02.053","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T02:49:24Z","timestamp":1741315764000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A Randomized Trial of Stereotactic Body Radiation Therapy vs Radiofrequency Ablation for the Treatment of Small Renal Masses: A Feasibility Study (RADSTER)"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2782-0648","authenticated-orcid":false,"given":"Raees","family":"Cassim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braden","family":"Millan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Mironov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Ahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Tajzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen","family":"Hoogenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmen","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Swaminath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2025.02.053_bib1","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0022-5347(05)65640-6","article-title":"The changing natural history of renal cell carcinoma","volume":"166","author":"Pantuck","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.02.053_bib2","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1001\/jama.281.17.1628","article-title":"Rising incidence of renal cell cancer in the United States","volume":"281","author":"Chow","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2025.02.053_bib3","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1159\/000019652","article-title":"Increase of renal cell carcinoma incidence in Central Europe","volume":"33","author":"Wunderlich","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.02.053_bib4","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2018.79.2341","article-title":"Current management of small renal masses, including patient selection, renal tumor biopsy, active surveillance, and thermal ablation","volume":"36","author":"Sanchez","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.urology.2025.02.053_bib5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1200\/JCO.2016.69.9645","article-title":"Management of small renal masses: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Finelli","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.urology.2025.02.053_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11912-020-00924-9","article-title":"Management of the small renal mass: a 2020 update","volume":"22","author":"Wilcox Vanden Berg","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.urology.2025.02.053_bib7","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/bju.13841","article-title":"Comprehensive assessment of renal tumour complexity in a large percutaneous cryoablation cohort","volume":"119","author":"Bhindi","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2025.02.053_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jvir.2019.09.011","article-title":"Long-term survival after percutaneous radiofrequency ablation of pathologically proven renal cell carcinoma in 100 patients","volume":"31","author":"Marshall","year":"2020","journal-title":"J Vasc Interv Radiol JVIR"},{"key":"10.1016\/j.urology.2025.02.053_bib9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.eururo.2019.04.026","article-title":"Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses","volume":"76","author":"Andrews","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.02.053_bib10","article-title":"Long-term outcomes of radiofrequency ablation vs partial nephrectomy for cT1 renal cancer: a meta-analysis and systematic review","volume":"9","author":"Li","year":"2023","journal-title":"Front Surg"},{"key":"10.1016\/j.urology.2025.02.053_bib11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.juro.2016.04.081","article-title":"Management of renal masses and localized renal cancer: systematic review and meta-analysis","volume":"196","author":"Pierorazio","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.02.053_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.critrevonc.2018.08.010","article-title":"Stereotactic body radiation therapy (SBRT) on renal cell carcinoma, an overview of technical aspects, biological rationale and current literature","volume":"131","author":"Francolini","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.urology.2025.02.053_bib13","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2025.02.053_bib14","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","article-title":"5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","volume":"23","author":"Siva","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urology.2025.02.053_bib15","unstructured":"Study Details | Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation for Small Renal Masses | ClinicalTrials.gov n.d. Accessed August 28, 2024. https:\/\/clinicaltrials.gov\/study\/NCT03811665."},{"key":"10.1016\/j.urology.2025.02.053_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.urology.2025.02.053_bib17","unstructured":"R Studio Team. RStudio: Integrated Development for R; 2022."},{"key":"10.1016\/j.urology.2025.02.053_bib18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2214\/AJR.14.14099","article-title":"Effect of stereotactic body radiotherapy on the growth kinetics and enhancement pattern of primary renal tumors","volume":"206","author":"Sun","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.urology.2025.02.053_bib19","doi-asserted-by":"crossref","unstructured":"SBRT in Localized Renal Carcinoma: A Review of the Literature | Anticancer Research n.d. Accessed September 9, 2022. https:\/\/ar.iiarjournals.org\/content\/42\/2\/667.long#ref-38.","DOI":"10.21873\/anticanres.15525"},{"key":"10.1016\/j.urology.2025.02.053_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818822329","article-title":"Renal cancer is not radioresistant: slowly but continuing shrinkage of the tumor after stereotactic body radiation therapy","volume":"18","author":"Funayama","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.urology.2025.02.053_bib21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.eururo.2023.03.025","article-title":"Stereotactic radiotherapy for renal cell carcinoma: the fallacy of (false) positive post-treatment biopsy?","volume":"84","author":"Correa","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.02.053_bib22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00345-010-0549-z","article-title":"The role of radiologic imaging and biopsy in renal tumor ablation","volume":"28","author":"Ortiz-Alvarado","year":"2010","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2025.02.053_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2020.10.031","article-title":"Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma","volume":"155","author":"Grubb","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.urology.2025.02.053_bib24","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urology.2025.02.053_bib25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2023.02.016","article-title":"Phase 2 trial of stereotactic ablative radiotherapy for patients with primary renal cancer","volume":"84","author":"Hannan","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.02.053_bib26","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(23)00513-2","article-title":"Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urology.2025.02.053_bib27","first-page":"398","article-title":"Surveillance post-radiofrequency ablation for small renal masses: recurrence and followup","volume":"14","author":"Lam","year":"2020","journal-title":"Can Urol Assoc J J Assoc Urol Can"},{"key":"10.1016\/j.urology.2025.02.053_bib28","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1464-410X.2012.11608.x","article-title":"Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results","volume":"111","author":"Karam","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2025.02.053_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/692014","article-title":"The natural history and predictors for intervention in patients with small renal mass undergoing active surveillance","volume":"2015","author":"Bahouth","year":"2015","journal-title":"Adv Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525002171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525002171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:42:04Z","timestamp":1762231324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429525002171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"alternative-id":["S0090429525002171"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2025.02.053","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Trial of Stereotactic Body Radiation Therapy vs Radiofrequency Ablation for the Treatment of Small Renal Masses: A Feasibility Study (RADSTER)","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2025.02.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}